Top Page
Nova Eye Medical
(Sydney:EYE)
Nova Eye Medical (EYE) vs. iShares MSCI Australia ETF (EWA)
Nova Eye Medical Business Overview & Revenue Model
Nova Eye Medical Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.27M | 29.27M | 23.32M | 17.02M | 13.38M | 13.39M |
| Gross Profit | 18.89M | 20.07M | 20.19M | 842.00K | -765.00K | 1.77M |
| EBITDA | -6.72M | -8.98M | -5.98M | -14.65M | -7.89M | -3.67M |
| Net Income | -9.06M | -9.06M | -8.79M | -15.29M | -7.50M | -4.36M |
Balance Sheet | ||||||
| Total Assets | 26.50M | 26.50M | 29.88M | 30.36M | 36.63M | 41.99M |
| Cash, Cash Equivalents and Short-Term Investments | 5.05M | 5.05M | 6.15M | 7.42M | 8.00M | 17.80M |
| Total Debt | 3.02M | 3.02M | 3.35M | 1.53M | 1.94M | 3.70M |
| Total Liabilities | 7.54M | 7.54M | 8.55M | 7.17M | 6.23M | 6.66M |
| Stockholders Equity | 18.97M | 18.97M | 21.33M | 23.19M | 30.40M | 35.34M |
Cash Flow | ||||||
| Free Cash Flow | -6.45M | -6.58M | -8.31M | -7.52M | -10.27M | -15.13M |
| Operating Cash Flow | -6.15M | -6.15M | -7.86M | -6.72M | -4.68M | -12.90M |
| Investing Cash Flow | -450.00K | -364.00K | -325.00K | -800.00K | -4.58M | -3.22M |
| Financing Cash Flow | 5.56M | 5.56M | 6.91M | 6.82M | -402.00K | -61.61M |
Nova Eye Medical Technical Analysis
Nova Eye Medical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$52.69M | -5.05 | -44.16% | ― | 25.47% | 14.08% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$25.54M | -2.66 | -103.74% | ― | 14.84% | 39.64% | |
48 Neutral | AU$78.91M | -57.25 | -6.35% | ― | 2.23% | -263.16% | |
46 Neutral | AU$130.03M | -9.69 | -31.98% | ― | 34.20% | -23.90% | |
44 Neutral | AU$164.50M | -15.43 | -70.55% | ― | ― | -257.32% | |
41 Neutral | AU$63.89M | -3.89 | -128.19% | ― | -14.25% | -22.83% |
Nova Eye Medical Corporate Events
Nova Eye Medical has scheduled an investor webinar for Monday, 2 February 2026 at 11:30 am AEDT, where Managing Director Tom Spurling will present the company’s quarterly results and provide an update on the iTrack Registry. Shareholders and interested investors can register online and will be able to submit questions ahead of time or participate in a live Q&A during the session, signalling the company’s continued engagement with its investor base and providing greater transparency around the performance and clinical uptake of its glaucoma treatment technologies.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical reported record global sales of US$6.1 million for the December 2025 quarter, up 38% year-on-year and 25% on the previous quarter, driven by strong demand for its iTrack technology in the US and accelerating growth in other regions. Last-twelve-month sales reached about US$21 million, growing roughly three times faster than the broader industry, while operating cash outflow was A$1.0 million, including a A$1.2 million working capital investment to support rapid sales expansion; management expects operating cashflow to continue improving as utilisation of iTrack grows and new markets such as China begin commercialising the recently approved iTrack Advance during 2026.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical has reported positive 12‑month clinical outcomes from its iTrack Global Data Registry, an independently managed, prospective real-world database now comprising more than 600 eyes contributed by 20 surgeons across 20 international sites. The latest annual statistical report shows 409 eyes with one-year follow-up, demonstrating an 85% success rate in reducing intraocular pressure in patients with baseline pressure above 18 mmHg and an average 40% reduction in medication use, alongside only six minor, self-resolving adverse events. These results compare favourably with other minimally invasive glaucoma surgery options and are expected to strengthen the clinical and safety case for canaloplasty with iTrack, supporting broader surgical adoption, payer engagement, market access, and future peer-reviewed publications that could further entrench Nova Eye’s position in the glaucoma treatment market.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical has released a presentation ahead of an investor webinar scheduled to discuss its December 2025 sales results, outlining the clinical context in which it operates by highlighting how blocked ocular drainage canals cause fluid build-up, raised intraocular pressure and eventual optic nerve damage. While the document is largely introductory and framed by standard investment disclaimers, it underscores the company’s focus on addressing glaucoma-related pathology, reinforcing its positioning within the eye-care market as it prepares to update investors on trading performance and the commercial traction of its glaucoma-focused technologies.
The most recent analyst rating on (AU:EYE) stock is a Sell with a A$0.15 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical has scheduled an investor webinar for Monday, 19 January 2026 at 11:30 am AEDT, during which Managing Director Tom Spurling will present a sales update for the six months ended 31 December 2025 and take questions from participants. The event signals an effort by the glaucoma-focused device maker to increase transparency and engagement with shareholders ahead of releasing detailed half-year figures, offering investors an early window into trading performance and operational momentum in its key markets.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical reported record global sales of US$6.1 million for the December 2025 quarter, up 38% year-on-year and 25% on the previous quarter, driving six‑month revenue to US$10.9 million, a 29% increase on the prior corresponding period. For the twelve months to 31 December 2025, group revenue reached about US$21 million, up 24% and roughly three times the estimated industry growth rate, underpinned by sustained strength in the US market—where iTrack Advance has delivered six consecutive halves of sales growth at an annualised rate of about 40%—and robust gains in Rest of World markets, while China lagged ahead of expected 2026 sales of iTrack Advance following its recent approval. These results, which are subject to audit, highlight Nova Eye’s accelerating market penetration in minimally invasive glaucoma surgery and reinforce its competitive positioning within the sector.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical Limited has announced the application for the quotation of 12,000 ordinary fully paid securities on the ASX, with an issue date of December 8, 2025. This move is part of an employee incentive scheme and signifies the company’s ongoing efforts to enhance its market presence and operational capabilities.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical Limited held its Annual General Meeting on 27 November 2025, where all resolutions were carried with significant majorities. The resolutions included the adoption of the remuneration report, the re-election of directors Victor Previn and Daniel Webb, and the approval of an employee incentive plan. The approval of these resolutions reflects strong shareholder support and is likely to positively impact the company’s governance and operational strategies.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical Limited has made significant strides in the glaucoma surgical devices market with its iTrack™ Advance, achieving a 26% increase in US sales and a record $29.3 million in revenue. The company is expanding globally, with regulatory approval in China and a strong presence in Germany, while enhancing production capabilities to meet growing demand.
The most recent analyst rating on (AU:EYE) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Nova Eye Medical stock, see the AU:EYE Stock Forecast page.
Nova Eye Medical Limited has announced an upcoming webinar featuring Dr. Mahmoud A. Khaimi, a renowned glaucoma specialist, who will discuss the clinical advantages of the company’s iTrack Advance™ surgical device. This event highlights Nova Eye Medical’s commitment to advancing ophthalmic treatment technologies and may enhance the company’s industry positioning by showcasing the effectiveness of their minimally invasive glaucoma solutions to stakeholders and potential clients.
Nova Eye Medical Limited has released a presentation for the quarter ending September 30, 2025, highlighting their ongoing efforts in addressing eye health issues, particularly those related to high intraocular pressure. The announcement underscores the company’s commitment to advancing medical technology solutions in the eye care sector, which could have significant implications for their market positioning and stakeholder interests.